Medullary thyroid carcinoma (MTC) · line 1 · Cabozantinib monotherapy (advanced/progressive RET-WT MTC, 1L; or RET-mutant where RET-selective unavailable)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CABOZANTINIB-MTC-1L |
| ID | IND-MTC-ADVANCED-1L-CABOZANTINIB-RET-WT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-MTC |
| Sources | SRC-NCCN-THYROID-2025 |
Notes
Alternative 1L for RET-WT advanced MTC and the practical first-line in access-constrained settings until selpercatinib / pralsetinib EAP / cross-border treatment is established.
Used By
Algorithms
ALGO-MTC-1L- ALGO-MTC-1L